Assessment of the quality of randomized controlled trials in treating coronary heart disease by Chinese patent medicine.
- Author:
Yong-Liang JIA
1
;
Fang-Yi HUANG
;
Shi-Kai ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Coronary Disease; drug therapy; Drugs, Chinese Herbal; therapeutic use; Humans; Phytotherapy; methods; Quality Control; Randomized Controlled Trials as Topic; Treatment Outcome
- From: Chinese Journal of Integrated Traditional and Western Medicine 2012;32(4):560-568
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the quality of randomized controlled trials (RCTs) on Compound Danshen Dripping Pill, Compound Danshen Tablet, Suxiao Jiuxin Pill, Tongxinluo Capsule, and isosorbide dinitrate (ISDN) in treating coronary heart disease angina.
METHODSRCT reports were retrieved from CNKI, Wanfang Data, PubMed, China Master Theses Full-text Database, Chinese Electronic Periodical Services, Social Sciences Citation Index, Science Direct, Cambridge Journals Online, and EBM Reviews. Qualities of RCTs were assessed according to Jadad scale, M scale, CONSORT 2010, and CONSORT for herbal medicine. Kendall correlations between basic study characteristics and qualities of included RCTs were analyzed using R statistical software.
RESULTSEighty-eight RCTs were included. The medians (means, 95% CIs) were 2.00 (2.09, [1.81,2.37]) for the Jadad scale, 4.00 (3.52,[2.95, 4.09]) for the M scale, 15.00 (15.39, [13.87, 16.91]) for the CONSORT 2010, and 19.00 (19.06,[17.16, 20.96]) for the CONSORT for herbal medicine. Only 9.09% (8/88) of RCTs were of high quality (Jadad score >2). These RCT quality measures were not correlated with individual items of reporting, such as sample sizes and follow-up periods.
CONCLUSIONSThe quality of RCTs on Chinese patent medicine compared with ISDN was not improved from 1997 to 2009. It is urgent to improve the design of RCTs and the report quality.
